Bonefos/Sodium clodronate
Each capsule of Bonefos Sodium Clodronate contains a disodium clodronate tetrahydrate corresponding to 400 mg of anhydrous disodium clodronate. Each ml of solution for injection contains disodium clodronate tetrahydrate corresponding to 60 mg of anhydrous disodium clodronate. Each 5 ml ampoule contains 300 mg of anhydrous disodium clodronate. 400 mg capsules of disodium clodronate tetrahydrate; Excipients q.s.p. Solution for injection 60 mg/ml of anhydrous disodium clodronate; Excipients q.s.p. Bottle with 20 capsules at 400 mg of disodium clodronate tetrahydrate. Box with 5 ampoules of 5 ml to 60 mg/ml of anhydrous disodium clodronate

Brand | Medicine Strength | Size | Price |
---|---|---|---|
- | 400mg | 120 Caps | 239.00 |
- | 800mg | 60 Tabs | 245.00 |
It looks like you missed filling in questions from the last consultation.Click Here to submit your response.
Notify me once available
No hidden fees
Secure checkout
UK Regulated online pharmacy
Trusted by over 100,000+ customers
Each capsule of Bonefos Sodium Clodronate contains a disodium clodronate tetrahydrate corresponding to 400 mg of anhydrous disodium clodronate.
Bonefos belongs to the group of medicines called bisphosphonates, which help prevent calcium loss from the bones. The active substance in Bonefos is clodronate disodium. This medication is indicated for the treatment of hypercalcemia (increased concentration of calcium in the blood) and osteolysis (absorption or destruction of bone) secondary to malignant tumors.
Bonefos is intended for the treatment of bone diseases. Bonefos contains sodium clodronate as an active component. Clodronate is chemically defined
as a bisphosphonate and is an analogue of natural pyrophosphate. Clodronate has a marked affinity for mineralized tissues such as bone, where it inhibits resorption bone, which may be abnormally enlarged due to malignant disease. Consequently, a reduction in high calcium concentration can be observed
in the blood and a decrease in the risk of fracture in patients being treated with Bonefos
Bonefos (sodium clodronate) is indicated for the treatment of increased resorption bone due to malignant diseases with or without hypercalcemia.
For the Osteoporosis doses, Always take Bonefos 400 mg capsules exactly as your doctor has told you. Ask your doctor or pharmacist if you have doubts.
Bonefos is primarily instilled via the kidneys (or kidneys). Therefore, during the treatment with Bonefos, you must drink an adequate amount of water, respecting the instructions detailed below. Bonefos capsules should be swallowed whole.
A daily dose of 1,600 mg (4 capsules) administered in a single dose is recommended. When higher doses are used, it is recommended to administer separately (as a second dose) the portion of the dose that exceeds 1,600 mg, as indicated below.
The single daily dose (or the first of the two doses) should preferably be taken in the morning, on an empty stomach, along with a glass of water. You should avoid eating, drinking other liquids than water, or taking other medications by mouth for the hour after taking Bonefos.
When two daily doses are used, the first should be taken as indicated above. The second dose should be taken between two meals, having to have passed more than two hours from the last meal. Also, you should wait an hour later until you eat again. During those two hours before taking the medicine and the hour after taking it, you will not be able to drink any liquid other than water or eat food or medicine.
In general, you should never take Bonefos with milk, food, or medicines that contain calcium or other divalent cations, such as antacids and iron preparations, since they can decrease the effect of Bonefos by altering its absorption (see "Using other medicines ”).
Children: Bonefos should not be administered to children.
Seniors: There are no special administration recommendations for the elderly. No specific adverse effects have been recorded for this age group.
Adults with normal kidney function: If you have high levels of calcium in the blood (hypercalcemia) due to malignant tumors, you will usually be treated with concentrated intravenous Bonephos. However, if you have been prescribed capsules, you should be given a high starting dose of 2,400 mg or 3,200 mg daily, and may gradually decrease to 1,600 mg daily, depending on your doctor's assessment of your response to treatment.
For the treatment of bone resorption (bone absorption) without hypercalcemia, your doctor will indicate the dose to take. Normally the starting dose is 1,600 mg daily, not exceeding 3,200 mg daily.
If you have kidney failure (kidney function disorder): In that case, your doctor will indicate the dose to take. Either way, since Bonefos is primarily excreted through the kidney, doses greater than 1,600 mg daily should not be administered continuously.
If you think the action of Bonefos is too strong or weak, tell your doctor or pharmacist.
Your doctor will indicate the duration of treatment with Bonefos. Do not stop the treatment sooner, as the desired effect may not be obtained.
Do not take a double dose to make up for a forgotten dose.
If you stop taking Bonefos 400 mg capsules: Do not stop Bonefos treatment unless your doctor has told you to. If you want to stop treatment with Bonefos, consult your doctor.
Like all medicines, Bonefos 400 mg capsules can cause side effects, although not everybody gets them.
The most frequent adverse effect is diarrhea, which is usually mild and is more commonly associated with high doses.
These adverse reactions can occur with both oral and intravenous treatment, although the frequency of reactions may vary.
Common (may affect up to 1 in 10 people).
- Asymptomatic hypocalcaemia (decrease in the concentration of calcium in the blood that does not produce symptoms)
- Diarrhea, nausea, vomiting (all usually mild)
- A slight increase in transaminases (liver enzymes), generally within normal limits.
Rare (may affect up to 1 in 1,000 people).
- Symptomatic hypocalcaemia (decrease in the concentration of calcium in the blood that does produce symptoms)
- The increased serum concentration of parathyroid hormone associated with a reduction in the concentration of calcium in the blood
- Increased serum alkaline phosphatase in patients with metastatic disease, may be due to liver and bone metastases.
- Increase in transaminases (liver enzymes) greater than twice the normal limits, but without being associated with an alteration in liver function
- Hypersensitivity reaction (allergy) manifesting as a skin reaction.
You can buy Bonefos online through one of the UK’s leading online pharmacies, Pharmacy Planet. It's easy and convenient. To do so, You will need to fill out a short assessment and the item will be delivered directly to your door. If you want to buy Bonefos online, use Pharmacy Planet, a UK pharmacy you can trust.

clinical consultation
Answer a few questions on your health and your fitness goals.

assessment
Our clinicians will review your clinical questionnaire to make sure treatment is right for you.

aboard!
Once approved, you will access our wealth of experience and resources curated by our team and begin your clinical weight loss journey.
Need Help?

Start your weight loss journey heading in the right direction. Our team are here to help. Whether you’re unsure about which medicine is right for you or need help navigating the world of weight loss drugs, our team are on hand to help you make the right decision. We can put you in touch with one of our experienced weight loss clinicians so you can be sure you’re making the best decision with the most accurate information.
To get in touch, contact our Customer Service team on 0800 978 8956 or email headoffice@pharmacyplanet.com.
References:
- Healthy Weight Loss In Depth - Mayo Clinic
- Orlistat-associated adverse effects and drug interactions: a critical review - PubMed - Theodosios D Filippatos 1, Christos S Derdemezis, Irene F Gazi, Eleni S Nakou, Dimitri P Mikhailidis, Moses S Elisaf
- Weight Loss Medicine - Patient Info - Authored by Dr Laurence Knott
- How to use Orlistat 120 Mg Capsule Fat Absorption Decreasing Agents - WebMD

Authored By
HARMINDER ‘HARMY’ KAUR
BSc(hons) Pharmacy
GPhC Number: 2061107

Reviewed By
GURDEV SEHMI
BSc Pharm, MRPharmS, Independent Prescriber, Superintendent Pharmacist, Clinical Lead
GPhC Number: 2050925